Biosynthetic enzymes of the SARS-CoV-2 as potential targets for the discovery of new antiviral drugs

Authors

  • Juan Alberto Castillo-Garit Unidad de Toxicología Experimental. Universidad de Ciencias Médicas de Villa Clara.(Cuba)
  • Yudith Cañizares-Carmenate Unit of Computer-Aided Molecular “Biosilico” Discovery and Bioinformatic Research (CAMD-BIR Unit), Facultad de Química-Farmacia. Universidad Central “Marta Abreu” de Las Villas. Santa Clara 54830. Villa Clara. Cuba.
  • Facundo Pérez-Giménez Unidad de Investigación de Diseño de Fármacos y Conectividad Molecular. Departamento de Química Física. Facultad de Farmacia. Universitat de València. España.

DOI:

https://doi.org/10.46583/nereis_2021.13.844

Keywords:

antiviral, coronavirus, COVID-19, target, enzyme

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised a major global health concern. This urgent situation is pressing the world to respond with the development of novel vaccine or small molecule therapeutics for SARS-CoV-2. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. Direct-acting agents, targeting specific viral enzymes that play an essential role in viral replication, represent a milestone in antiviral therapy. Several biosynthetic enzymes of the SARS-CoV-2 were analyzed as potential targets to develop new therapeutic drugs. This work provides a basis and directions for future drug development and reuse on the protein level of COVID-19.

Downloads

Download data is not yet available.

References

Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. Nat Rev Drug Discov. 2016;15:327-47.

Cannalire R, Cerchia C, Beccari AR, Di Leva FS, Summa V. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. J Med Chem. 2020.

Dai W, Zhang B, Jiang X-M, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331.

Zhu W, Xu M, Chen CZ, Guo H, Shen M, Hu X, et al. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacol Transl Sci. 2020;3(5):1008-16.

Zhang Y, Tang LV. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. J Proteome Res. 2021;20(1):49-59.

Impact of COVID-19 in the World: Worldmeter; 2021.

Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):812-27.e19.

WHO. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int2021.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9.

Saglietto A, D’Ascenzo F, Zoccai GB, De Ferrari GM. COVID-19 in Europe: the Italian lesson. Lancet. 2020;395(10230):1110-1.

Van Lancker W, Parolin Z. COVID-19, school closures, and child poverty: a social crisis in the making. Lancet Public Health. 2020;5(5):e243-e4.

Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID- 19. Lancet Infect Dis. 2020;20(6):631-3.

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58.

Alpern JD, Gertner E. Off-Label Therapies for COVID-19 —Are We All In This Together? Clin Pharmacol Ther. 2020;108(2):182-4.

Everts M, Cihlar T, Bostwick JR, Whitley RJ. Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. Annu Rev Pharmacol. 2017;57(1):155-69.

Covid vaccine development: The shots available and the doses administered; 2021.

Zarandi PK, Zinatizadeh MR, Zinatizadeh M, Yousefi MH, Rezaei N. SARS-CoV-2: From the Pathogenesis to Potential Anti-viral Treatments. Biomedicine & Pharmacotherapy. 2021:111352.

Ton A-T, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol Inform. 2020;39(8):2000028.

Chen YW, Yiu C-PB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research. 2020;9:129.

Frick DN, Lam AMI. Understanding Helicases as a Means of Virus Control. Current Pharmaceutical Design. 2006;12(11):1315-38.

Ogando NS, Ferron F, Decroly E, Canard B, Posthuma CC, Snijder EJ. The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity. Frontiers in Microbiology. 2019;10(1813).

Published

2021-11-15